S100P interacts with integrin α7 and increases cancer cell migration and invasion in lung cancer
Metrics: PDF 873 views | HTML 1028 views | ?
Ya-Ling Hsu1, Jen-Yu Hung2,3, Yung-Yu Liang1, Yi-Shiuan Lin1, Ming-Ju Tsai1,2, Shah-Hwa Chou4, Chi-Yu Lu5 and Po-Lin Kuo6,7
1 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
2 Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
3 School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
4 Division of Chest Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
5 Department of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan
6 Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
7 Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung, Taiwan
Po-Lin Kuo, email:
Keywords: S100P, ZEB1, FAK, metastasis, oncogene
Received: April 07, 2015 Accepted: July 16, 2015 Published: July 22, 2015
S100P, a Ca2+ binding protein, has been shown to be overexpressed in various cancers. However, its functional character in lung cancer remains largely unknown. In this study, we show that S100P increases cancer migration, invasion and metastasis in lung cancer cells. Ectopic expression of S100P increases migration, invasion and EMT in less invasive CL1-0 lung cancer cells. Conversely, knockdown of S100P suppressed migration and invasion, and caused a reversion of EMT in highly invasive lung cancer cells. These effects were transduced by increasing the interaction of S100P with integrin α7, which activated focal adhesion kinase (FAK) and AKT. Blocking FAK significantly decreased S100P-induced migration by decreasing Src and AKT activation, whereas inhibiting AKT reduced S100P upregulation on ZEB1 expression. Further study has indicated that S100P knockdown prevents the spread of highly metastatic human lung cancer in animal models. This study therefore suggests that S100P represents a critical activator of lung cancer metastasis. Detection and targeted treatment of S100P-expressing cancer is an attractive therapeutic strategy in treating lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.